Ito, Takumi

Identification of a Primary Target of Thalidomide Teratogenicity

Ito, T., Ando, H., Suzuki, T., Ogura, T., Hotta, K., Imamura, Y., Yamaguchi, Y., & Handa, H. (2010) · Science

Pharmacological Effects and Toxicity StudiesDevelopmental Biology and Gene Regulation

Cited by 2,136

Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide

Lopez-Girona, A., Mendy, D., Ito, T., Miller, K., Gandhi, A. K., Kang, J., Karasawa, S., Carmel, G., Jackson, P., Abbasian, M., et al. (2012) · Leukemia

Protein Degradation and InhibitorsMultiple Myeloma Research and Treatments

Cited by 814

A novel cereblon modulator recruits GSPT1 to the CRL4CRBN ubiquitin ligase

Matyskiela, M. E., Lu, G., Ito, T., Pagarigan, B., Lu, C.-C., Miller, K., Fang, W., Wang, N.-Y., Nguyen, D., Houston, J., et al. (2016) · Nature

Protein Degradation and InhibitorsUbiquitin and proteasome pathways

Cited by 701

Immunomodulatory agents lenalidomide and pomalidomide co‐stimulate Tcells by inducing degradation of Tcell repressors Ikaros and Aiolos via modulation of the E 3 ubiquitin ligase complex CRL 4 CRBN

Gandhi, A. K., Kang, J., Havens, C. G., Conklin, T., Ning, Y., Wu, L., Ito, T., Ando, H., Waldman, M. F., Thakurta, A., et al. (2014) · British Journal of Haematology

Protein Degradation and InhibitorsUbiquitin and proteasome pathways

Cited by 619

Structure of the human Cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogs

Chamberlain, P. P., Lopez-Girona, A., Miller, K., Carmel, G., Pagarigan, B., Chie-Leon, B., Rychak, E., Corral, L. G., Ren, Y. J., Wang, M., et al. (2014) · Nature Structural & Molecular Biology

Protein Degradation and InhibitorsUbiquitin and proteasome pathways

Cited by 531

p63 is a cereblon substrate involved in thalidomide teratogenicity

Asatsuma-Okumura, T., Ando, H., De Simone, M., Yamamoto, J., Sato, T., Shimizu, N., Asakawa, K., Yamaguchi, Y., Ito, T., Guerrini, L., et al. (2019) · Nature Chemical Biology

Protein Degradation and InhibitorsPharmacological Effects and Toxicity Studies

Cited by 134

Cereblon and its downstream substrates as molecular targets of immunomodulatory drugs

Ito, T., & Handa, H. (2016) · International Journal of Hematology

Protein Degradation and InhibitorsMultiple Myeloma Research and Treatments

Cited by 84

Genome-wide screening reveals a role for subcellular localization of CRBN in the anti-myeloma activity of pomalidomide

Tateno, S., Iida, M., Fujii, S., Suwa, T., Katayama, M., Tokuyama, H., Yamamoto, J., Ito, T., Sakamoto, S., Handa, H., et al. (2020) · Scientific Reports

Protein Degradation and InhibitorsUbiquitin and proteasome pathways

Cited by 36

Small-molecule HDAC and Akt inhibitors suppress tumor growth and enhance immunotherapy in multiple myeloma

Hirano, M., Imai, Y., Kaito, Y., Murayama, T., Sato, K., Ishida, T., Yamamoto, J., Ito, T., Futami, M., Ri, M., et al. (2021) · Journal of Experimental & Clinical Cancer Research

Multiple Myeloma Research and TreatmentsProtein Degradation and Inhibitors

Cited by 25